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ALT alanine amino transferase 25 
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IGG immunoglobulin G 34 
ITP immune thrombocytopenic purpura 35 
kg  kilogram 36 
m2  meter squared 37 
mg  miligram 38 
mm3  milimeter cubed 39 
MMF mycophenolate mofetil 40 
PCR polymerase chain reaction 41 
PRCA pure red cell aplasia 42 
RBC red blood cells 43 
SOT solid organ transplant 44 
WBC white blood count 45 
Abstract 46 
 47 
Acquired pure red call aplasia (PRCA) and autoimmune hemolytic anemia (AIHA) are rare 48 
complications of immunosuppression in pediatric solid organ transplant patients. We report a 14-49 
month-old female who developed Coombs positive hemolytic anemia and reticulocytopenia while 50 
on tacrolimus after cardiac transplantation. She was successfully treated with rituximab after failing 51 
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treatment with corticosteroids and intravenous immunoglobulins. Clinicians should consider PRCA 52 
differential diagnosis in a patient presenting with reticulocytopenia and hemolysis. In addition, the 53 
coexistence of PRCA with AIHA, and the response to therapy with rituximab supports a common 54 
immune mediated pathogenesis for both disorders. 55 
 56 
 57 
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 59 
 60 
 61 
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Introduction 70 
Acquired pure red call aplasia (PRCA) and autoimmune hemolytic anemia (AIHA) are rare 71 
complications in pediatric solid organ transplant(SOT) patients with incidence of about 5.6%(1). 72 
PRCA is characterized by severe normocytic anemia, reticulocytopenia and erythroblastopenia(1, 2). 73 
Congenital forms of PRCA, such as Diamond Blackfan Anemia are caused by genetic defects affecting 74 
the erythropoietic lineage(3). Acquired PRCA is associated with malignancy, infections, connective 75 
tissue disorders, pregnancy and drugs(1). In SOT recipients, PRCA is most commonly caused by 76 
parvovirus B19 infection and immunosuppression with aziathioprine, mycophenolate mofetil(MMF) 77 
and tacrolimus being commonly implicated(4). AIHA, on the other hand, is characterized by 78 
normocytic anemia, unconjugated hyperbilirubinemia and reticulocytosis caused by increased 79 
destruction of red blood cells(RBCs) by anti-RBC autoantibodies with and without complement 80 
activation(5).  81 
 82 
Although there are reports of either PRCA or AIHA in SOT patients on treatment with tacrolimus, to 83 
our knowledge, there are no prior reports of both disorders coexisting in pediatric patients being 84 
treated with tacrolimus(6-8). We describe a 14-month-old infant who developed PRCA and AIHA 85 
while on post cardiac transplant immunosuppressive therapy with tacrolimus to make clinicians 86 
aware of this rare presentation of PRCA and its treatment. We hypothesize that AIHA and PRCA 87 
share a common immune mediated pathogenesis and review the literature supporting this 88 
hypothesis.   89 
 90 
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 91 
Case Presentation 92 
The patient is a full-term infant with congenital heart block who had a pacemaker placed at 2-days of 93 
life.  She developed severe cardiogenic shock at age 3-months and was diagnosed with idiopathic 94 
cardiomyopathy, CMV hepatitis and hypothyroidism. She was bridged with a ventricular assist device 95 
and started on valganciclovir and levothyroxine. At age 7-months she underwent a living donor 96 
cardiac transplantation procedure.  She was transfused with packed-RBC, platelets, fresh frozen 97 
plasma and cryoprecipitate peri-operatively without complications and was started on 98 
immunosuppression with MMF and cyclosporine post-operatively. Due to concerns for early 99 
rejection, cyclosporine was switched to tacrolimus soon after her first birthday. She presented at 14-100 
months of age with one-week history of worsening lethargy and vomiting. Physical examination 101 
revealed severe pallor, but no jaundice, hepatomegaly or splenomegaly. Hemoglobin was 3.2g/dl, 102 
reticulocyte 5.8x103/mm3, and peripheral smear showed normocytic normochromic anemia without 103 
significant anisopoikilocytosis[Figure 1A]. WBC was 8.6x103/mm3, and platelets, 581x103/mm3. LDH 104 
was mildly elevated at 470U/l, haptoglobin low at <10mg/dl, and bilirubin normal. Direct 105 
antiglobulin test(DAT) was positive with anti-IgG and C3d specificity and alloantibodies present on 106 
adsorption, consistent with immune mediated hemolysis. Liver enzymes were elevated(AST 236U/l 107 
and ALT 663U/l).  Respiratory viral panel, parvovirus, plasma CMV and EBV DNA PCRs were all 108 
negative.  She was transfused to a hemoglobin of 7g/dl and discharged home. She became 109 
progressively tired and sleepy and was readmitted 5-days later with hemoglobin of 2.9g/dl and 110 
reticulocytes of 4.4x103/mm3.  The patient was again transfused and started on a 3-day course of 111 
intravenous methylprednisolone(2mg/kg/day) followed by oral prednisone(2mg/kg/day). She 112 
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required transfusions every other day to maintain the hemoglobin above 7g/dl even after 3-weeks. A 113 
two-day course of intravenous immunoglobulin(1g/kg) was given with neither improvement in 114 
reticulocyte count nor transfusion needs.  At this point, we suspected a central cause and performed 115 
a bone marrow aspirate and biopsy which revealed hypocellularity(50%) with markedly decreased 116 
erythroid precursors, consistent with PRCA[Figure 1B and 1C]. She was started on four weekly doses 117 
of rituximab(375mg/m2/dose) with significant improvement in the anemia and reticulocytopenia 118 
after the first dose[Figure 2]. One-week after the first infusion, she was no longer transfusion 119 
dependent and was discharged home on prednisone taper. Her hemoglobin then was 11.3g/dl and 120 
reticulocyte count 299x103/mm3. This reticulocytosis resolved by the 3-month follow-up. Infectious 121 
complications included a norovirus infection and cellulitis of the finger both of which resolved on 122 
supportive care and antibiotics.  123 
 124 
Discussion 125 
This is one of the first reported pediatric cases of concurrent PRCA and AIHA associated with 126 
tacrolimus. Due to the rarity of this combined presentation, clinicians may fail to consider PRCA as a 127 
possible differential diagnosis in AIHA patients having reticulocytopenia especially as this can be 128 
seen in association with normoblastic hyperplasia in 37% of cases of AIHA(9, 10). Reticulocytopenia 129 
in these patients is thought to reflect a concomitant immune mediated destruction of RBC 130 
precursors, a temporary infection induced suppression of hematopoiesis or a delayed bone marrow 131 
response to hemolysis(9). These differ from the typical findings on bone marrow evaluation in PRCA 132 
which are complete or near complete absence of erythroid precursors. Although the bone marrow is 133 
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usually cellular with unaffected hematopoiesis in the non-erythroid cell lines(1), hypocellularity and 134 
a markedly elevated myeloid:erythroid ratio, as in our patient has been described(11) .   135 
 136 
PRCA occurring in association with AIHA has been reported in association with hepatitis A, 137 
immunosuppressive therapy, lupus(12), lymphoma(13), and Sjogren’s syndrome(14) , CMV and EBV 138 
infection(15) and in children with no underlying medical problems(16). The interval between onset 139 
of PRCA and AIHA varies widely from simultaneous occurrence to 4 years between PRCA and AIHA(2, 140 
17). Post-transplant AIHA and PRCA is generally associated with immunosuppressive therapy.  141 
Alemtuzumab, MMF and daclizumab have been implicated(1). Although tacrolimus, another 142 
immunosuppressant commonly used in pediatric SOT, has been associated with AIHA or PRCA, the 143 
coexistence of both disorders has not been reported to date with tacrolimus.   144 
 145 
This case also provides further insight for the possible pathogenesis for PRCA in these patients. 146 
Acquired PRCA other than parvovirus B19 are thought to be immune mediated based on the 147 
response of these patients to immunosuppression. Soluble serum inhibitors and inhibitory T-cells are 148 
believed to inhibit the in vitro growth of and destroy erythroid precursors(3, 16). Support for 149 
immune mediated destruction is provided by patients, like ours, in whom PRCA coexists with other 150 
known immune disorders like AIHA or ITP. In these patients, the anemia and reticulocytopenia may 151 
be due to an accelerated destruction of both erythrocytes and erythroid precursors mediated by a 152 
common lineage specific antibody(3, 18). Support for this comes from the isolation of pan-153 
agglutinating auto-antibodies from sera of a group of patients on immunosuppression post SOT(1), a 154 
finding comparable to other PRCA pateints in whom, a single antibody directed against both 155 
  
 
This article is protected by copyright. All rights reserved. 
9 
 
erythroid precursors and mature RBCs was identified(19). The generation of these antibodies in 156 
patients on immunosuppressants, is thought to occur through immune dysregulation(1). Although 157 
CMV could be a potential cause of PRCA in this patient, the timing of the PRCA and the absence of 158 
significant viremia, which has been described in other cases, makes CMV less likely(15).  159 
 160 
The treatment of AIHA involves the use of corticosteroids, IVIG and rituximab in patients who fail 161 
first line therapy. Corticosteroids are the first line treatment in patients with PRCA although relapse 162 
can occur in 80% of patients during the first year after remission(20). Cyclosporin A may be a better 163 
option when long-term maintenance is considered(11). Rituximab has been used successfully in the 164 
treatment of PRCA in patients on immunosuppressants(16). Our patient received 4 weekly doses 165 
with good response without discontinuing her tacrolimus. Since she was only 7-months post-166 
transplant, it was vital to continue immunosuppression to prevent rejection. Rituximab may also play 167 
an additive immunosuppressive role especially in those patients whom humoral mechanisms may be 168 
mediating graft rejection.  169 
 170 
Clinicians should be aware of this possible coexistence of PRCA and AIHA in patients on 171 
treatment with tacrolimus who present with reticulocytopenia and consider performing a bone 172 
marrow evaluation in these patients. Rituximab may offer an option for therapy in a selected 173 
group of these patients.  174 
 175 
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LIST OF FIGURE LEGENDS 248 
 249 
 250 
Figure 1: The peripheral blood smear normocytic normochromic anemia without significant 251 
anisopoikilocytosis [A]. Bone marrow preparations showed a hypocellular bone marrow 252 
(50%) cellularity [B and C] with markedly decreased erythroid precursors, normal 253 
megakaryocytes and normal granulopoiesis with no increase in blasts. 254 
 255 
Figure 2: Hemoglobin and reticulocyte counts showed improvement with stable hemoglobin 256 
levels and significant improvement in reticulocyte count following the first dose of rituximab. 257 
The transfusion requirements also improved significantly and the patient was off transfusion 258 
within the first week following rituximab. Her steroids were also tapered. She remained 259 
stable at follow up 3 months after rituximab therapy. 260 
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